Allarity Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-09$1.76 RISE2026-02-05$0.81 PEAK2026-04-22$1.40 195d | -54.0% 119d | Missed | Missed | — | — | +72.8% 76d | Missed |
DROP2025-09-05$1.97 RISE2025-12-22$0.98 PEAK2026-03-12$1.35 188d | -50.3% 108d | Missed | Missed | — | — | +37.8% 80d | Missed |
DROP2025-09-05$1.97 RISE2025-11-20$0.99 PEAK2025-11-28$1.33 84d | -49.6% 76d | Missed | Missed | — | — | +33.9% 8d | Missed |
DROP2025-04-30$1.20 RISE2025-08-20$0.87 PEAK2025-09-05$1.97 128d | -27.6% 112d | Missed | Missed | — | — | +126.7% 16d | Missed |
DROP2025-01-27$1.54 RISE2025-06-05$0.80 PEAK2025-09-02$1.60 218d | -48.1% 129d | Missed | Missed | — | — | +100.3% 89d | Missed |
DROP2025-01-27$1.54 RISE2025-04-09$0.70 PEAK2025-04-30$1.20 93d | -54.4% 72d | Missed | Missed | — | — | +70.9% 21d | Missed |
DROP2024-10-18$1.73 RISE2025-02-25$0.71 PEAK2025-04-30$1.20 194d | -59.2% 130d | Missed | Missed | — | — | +70.2% 64d | Missed |
DROP2024-08-19$5.82 RISE2024-12-16$0.96 PEAK2025-01-27$1.54 161d | -83.6% 119d | Missed | Missed | — | — | +61.3% 42d | Missed |
DROP2024-03-28$180.60 RISE2024-08-07$4.20 PEAK2024-08-19$5.82 144d | -97.7% 132d | Missed | Missed | — | — | +38.6% 12d | Missed |
DROP2023-07-06$2,286.00 RISE2023-11-10$282.00 PEAK2023-12-04$360.00 151d | -87.7% 127d | Missed | Missed | — | — | +27.7% 24d | Missed |
DROP2022-06-03$2,511,600.00 RISE2022-09-06$873,600.00 PEAK2022-09-08$1,092,000.00 97d | -65.2% 95d | Missed | Missed | — | — | +25.0% 2d | Missed |
DROP2022-06-03$2,511,600.00 RISE2022-07-25$915,600.00 PEAK2022-08-18$1,276,800.00 76d | -63.5% 52d | Missed | Missed | — | — | +39.4% 24d | Missed |
DROP2022-01-07$9,030,000.00 RISE2022-05-12$932,400.00 PEAK2022-06-03$2,511,600.00 147d | -89.7% 125d | Missed | Missed | — | — | +169.4% 22d | Missed |
No scored news yet for a sentiment trend.
Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share
Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast Track designation, in advanced ovarian cancer- Allarity has received a Notice of Allowance for new...
TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. , a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib —a differentiated, dual PARP...
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA approval following
Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancerSupports accelerating stenoparib...
Allarity Therapeutics Inc: Allarity Therapeutics announces that the stenoparib drp® test has received a notice of allowance from the US Patent and Trademark Office Allarity Therapeutics Inc -...
New AACR data highlight stenoparib’s potential in colorectal cancer through WNT pathway modulationThe Stenoparib-DRP® companion diagnostic is associated with enhanced overall...
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.5 to $9.75.
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 87.79 percent increase over losses of $(1.72) per share from the same period last
Allarity (ALLR) Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: a promissory note in the original principal amount of $10,930,000 and a secured promissory note in the original principal amount of $10,000,000, together providing approximately $20 million in net proceeds to the Company. The financing is expected to extend
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway
SEC.
This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Department of Veterans Affairs and is open to enrollment at 11 VA sites throughout the US TARPON SPRINGS, Fla., February 3, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALLR | +26.15% | +64.82% | +51.85% | +89.16% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +23.18% | +70.54% | +55.30% | +76.47% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 228.1K | $248.61K | 0.00% | Trimmed-7.9% | 2026-03-31 |
| StateStreet | passive | 137.6K | $149.98K | 0.00% | Unchanged | 2026-03-31 |
| TwoSigma | quant | 27.5K | $29.97K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | -0.22 | -0.17 | +22.73% |
| 2026-03-30 | -0.22 | -0.21 | +4.55% |
| 2025-11-14 | -0.23 | -0.19 | +17.39% |
| 2025-08-15 | -0.21 | -0.15 | +28.57% |
| 2024-11-14 | -8.40 | -1.75 | +79.19% |
| 2024-08-05 | -8.70 | -3.30 | +62.07% |
| 2024-05-14 | -52.80 | -664.20 | -1157.95% |
| 2023-11-14 | -4902.00 | -1344.00 | +72.58% |
| 2023-08-14 | -6714.01 | -15768.02 | -134.85% |
| 2023-05-11 | -189120.19 | -106320.11 | +43.78% |
| 2023-03-13 | -352800.71 | -193200.39 | +45.24% |
| 2022-11-14 | -210000.42 | -571201.14 | -172.00% |
| 2022-08-22 | -579601.16 | -436800.87 | +24.64% |
| 2022-05-27 | -554401.11 | 414683.63 | +174.80% |